Management of EGFR-mutant non-small-cell lung cancer patients after first-line reversible EGF receptor-tyrosine kinase inhibitors
2012 ◽
Vol 12
(11)
◽
pp. 1429-1435
◽
2017 ◽
Vol 6
(3)
◽
pp. 161-165
◽
2014 ◽
Vol 3
(2)
◽
pp. 403-407
◽
2013 ◽
Vol 39
(5)
◽
pp. 489-497
◽
2014 ◽
Vol 46
(4)
◽
pp. 323-330
◽